Functional polymorphisms in the human beta4 subunit of nicotinic acetylcholine receptors.
Human nicotinic acetylcholine receptor (nAChR) polymorphisms occur in different ethnic populations and may result in differences in nAChR ion channel properties. We have identified four nAChR beta 4 subunit (beta4) nucleotide variants: 392C-->T, 526C-->T, 538A-->G, and 1519A-->G. Their corresponding amino acid substitutions are: Thr to Ile at codon 91 (T91I), Arg to Trp at codon 136 (R136W), Ser to Gly at codon 140 (S140G), and Met to Val at codon 467 (M467V), respectively. The nAChR ion channel properties of these variants were studied and compared with the more-common (wild-type) allele as wild-types. The nAChRs (alpha4beta4 channels) were expressed heterologously in Xenopus oocytes and studied using the two-electrode voltage clamp technique to reveal functional differences between the wild-type and the variants. The receptors containing the R136W and M467V mutations (or variants) had a higher sensitivity to acetylcholine and lower EC50 than the wild-type. The T91I mutation had lower sensitivity to acetylcholine and the EC50 was larger than in wild-type nAChRs. The S140G mutation had a dose-response relationship that was similar to the wild-type. The T91I, R136W, and M467V mutations (or variants) also showed a slightly greater degree of steady-state desensitization than the wild-type in response to a 30-min exposure to one tenth of their EC50. The present results demonstrate that human beta4 nAChR DNA polymorphisms result in functional changes, and suggest that certain individuals with those variants may be more or less sensitive to cholinergic drugs or to dysfunctions associated with nicotinic cholinergic systems.
Liang
Yong
Y
Department of Neuroscience, Baylor College of Medicine, Houston, Texas 77030, USA.
Salas
Ramiro
R
Marubio
Lisa
L
Bercovich
Dani
D
De Biasi
Mariella
M
Beaudet
Arthur L
AL
Dani
John A
JA
D019943:Amino Acid Substitution; D003062:Codon / Q000235:genetics; D017931:DNA Primers; D014644:Genetic Variation; D006801:Humans; D008564:Membrane Potentials / Q000502:physiology; D009419:Nerve Tissue Proteins / Q000235:genetics* / Q000502:physiology; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D021122:Protein Subunits / Q000235:genetics; D011978:Receptors, Nicotinic / Q000235:genetics* / Q000502:physiology; D011994:Recombinant Proteins / Q000378:metabolism
C447159:CHRNB4 protein, human; D003062:Codon; D017931:DNA Primers; D009419:Nerve Tissue Proteins; D021122:Protein Subunits; D011978:Receptors, Nicotinic; D011994:Recombinant Proteins
Brain Res Brain Res Rev. 1998 May;26(2-3):198-216
9651527
J Comp Neurol. 2000 Sep 11;425(1):58-69
10940942
J Neurosci. 1999 Nov 1;19(21):9298-305
10531434
Neuron. 1996 May;16(5):905-8
8630247
Nature. 2004 Aug 19;430(7002):896-900
15318223
Nature. 1999 Apr 29;398(6730):805-10
10235262
Neuroscience. 1998 Dec;87(3):659-73
9758232
Addict Behav. 2004 Feb;29(2):261-72
14732415
Trends Neurosci. 2002 Apr;25(4):171-2
11998680
Pharmacol Biochem Behav. 2001 Dec;70(4):439-46
11796143
J Comp Neurol. 1989 Jun 8;284(2):314-35
2754038
Biophys J. 1994 Mar;66(3 Pt 1):646-53
7516721
Mol Pharmacol. 2002 Mar;61(3):695-705
11854451
J Neurosci. 2001 Mar 1;21(5):1452-63
11222635
J Neurobiol. 2002 Dec;53(4):431-46
12436411
Science. 1984 Sep 21;225(4668):1335-45
6382611
Lancet. 1992 May 23;339(8804):1268-78
1349675
Eur J Neurosci. 1995 Apr 1;7(4):647-55
7620615
Mol Pharmacol. 2003 Mar;63(3):574-80
12606764
Neuropharmacology. 2004 Sep;47(3):401-7
15275829
Nat Genet. 1995 Oct;11(2):201-3
7550350
Epilepsia. 2002;43 Suppl 5:112-22
12121305
Tob Control. 2000;9 Suppl 2:II4-8
10841585
Biophys J. 1996 Oct;71(4):1659-71
8889144
J Neurosci. 2000 Jan 1;20(1):66-75
10627582
Nature. 2003 Jun 26;423(6943):949-55
12827192
Nature. 2001 Feb 15;409(6822):928-33
11237013
Eur J Neurosci. 1994 Mar 1;6(3):478-85
8019684
J Pharmacol Exp Ther. 1997 Jan;280(1):346-56
8996215
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2786-91
11226318
Nature. 1997 Nov 27;390(6658):401-4
9389479
Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7280-4
7688475
Br J Pharmacol. 1998 Oct;125(4):751-60
9831911
Biochemistry. 2000 Apr 25;39(16):4666-73
10769122
Nat Rev Neurosci. 2002 Feb;3(2):102-14
11836518
Eur J Neurosci. 1994 Oct 1;6(10):1596-604
7850023
J Biol Chem. 1996 Jul 26;271(30):17656-65
8663494
Annu Rev Pharmacol Toxicol. 2000;40:431-58
10836143
Brain Res Mol Brain Res. 1992 Dec;16(3-4):339-44
1337943
Biophys J. 1984 Aug;46(2):277-83
6478036
J Physiol Paris. 1998 Apr;92(2):63-74
9782446
J Neurosci. 2003 Jul 16;23(15):6255-63
12867510
Nature. 1991 Oct 31;353(6347):846-9
1719423
J Neurosci. 1993 Jun;13(6):2680-8
8501532
J Hum Genet. 2001;46(7):362-6
11450844
Genet Test. 2003 Fall;7(3):189-94
14641994
J Gen Physiol. 2002 Oct;120(4):483-96
12356851
Am J Hum Genet. 2001 Jan;68(1):225-31
11104662
Neuron. 2001 Jul 19;31(1):131-41
11498056
Learn Mem. 2004 Jan-Feb;11(1):60-9
14747518
Neuropharmacology. 1999 Jun;38(6):769-83
10465681
Nature. 2001 May 17;411(6835):269-76
11357122
Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12689-94
9770547